重组人血管内皮抑制素联合化疗治疗老年晚期大肠癌临床观察

Clinical observation of recombinant human endostatin combined with chemotherapy for elderly patients with advanced colon cancer

目的观察重组人血管内皮抑制素(恩度)联合化疗治疗老年晚期大肠癌的近期疗效和毒副反应。方法 30例老年晚期结大肠癌患者为治疗组,35例非老年晚期结大肠癌患者为对照组,治疗组接受重组人血管内皮抑制素联合XELOX方案化疗。按照RECIST标准评价近期疗效,毒性反应按照WHO抗癌药物急性和亚急性毒性表现和分级标准评价。结果 65例患者64例可评价疗效,1例患者无法评价疗效;其中治疗组治疗的30例患者中,CR 3例,PR 16例,SD 8例,PD 3例,有效率63.3%。对照组治疗的35例患者中,CR 1例,获PR 12例,获SD 17例,PD 5例,1例无法评价疗效,有效率37.1%。主要毒副反应为骨髓抑制,食欲不振、乏力、腹泻、便秘等胃肠道反应,心脏毒副及外周神经毒性。结论老年晚期大肠癌患者可以耐受重组人血管内皮抑制素联合化疗,疗效好,毒副性低,值得临床进一步观察老年晚期大肠癌患者的使用情况。

Objective To observe the immediate efficacy and adverse toxic reactions of recombinant human endostatin injection（endostar） combined with chemotherapy for elderly patients with advanced colon cancer.Methods Thirty elderly patients with advanced colon cancer were included in the treatment group and 35 non-elderly patients in the control group.The treatment group received endostar combined with XELOX chemotherapy.The immediate efficacy was evaluated in accordance with RECIST standards.Adverse toxic reactions were evaluated according to WHO standards which classified anti-cancer drugs into acute and subacute types.Results Among 65 patients,64 were evaluable in efficacy and 1 patient was not evaluable.Among 30 patients in the treatment group,there were 3 CR,16 PR,8 SD,and 3 PD with an overall efficacy rate of 63.3%.Among the 35 patients in the control group,there were 1 CR,12 PR,17 SD and 5 PD.One patient was not evaluable.The overall efficacy rate was 37.1%.Main adverse and toxic reactions included myelo suppression,gastrointestinal reactions such as loss of appetite,fatigue,diarrhea,and constipation,cardiac toxicity and peripheral neurotoxicity.Conclusion Endostar combined with chemotherapy in the treatment of advanced colon cancer demonstrates good efficacy with lower toxicity.More clinical research can be conducted to further observe its use in elderly patients with advanced colon cancer.